BRAINLIFE.ORG




Current Neuro-Oncology




Volume 25 Number 17
15 September 2023




Home > Publications > Current Neuro-Oncology > Volume 25, Year 2023 > Number 17, 15 September






Ansari SA, Roohi M, Al Doseri KA, Alsindi KA, Almayman TA.
Glioblastoma with Primitive Neuroectodermal Tumor like Component: Rare and Enigmatic.
Gulf J
Oncolog. 2023 Sep;1(43):74-77. PMID: 37732531. Case report. ˍ



*

Umemura Y, Orringer D, Junck L, Varela ML, West MEJ, Faisal SM, Comba A, Heth J, Sagher O, Leung D, Mammoser A, Hervey-Jumper S, Zamler D, Yadav VN, Dunn P, Al-Holou W, Hollon T, Kim MM, Wahl DR, Camelo-Piragua S, Lieberman AP, Venneti S, McKeever P, Lawrence T, Kurokawa R, Sagher K, Altshuler D, Zhao L, Muraszko K, Castro MG, Lowenstein PR.
Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial.
Lancet Oncol. 2023 Sep;24(9):1042-1052
. doi: 10.1016/S1470-2045(23)00347-9. PMID: 37657463. Interventional study˰ ˍ




Sun L, Kienzler JC, Reynoso JG, Lee A, Shiuan E, Li S, Kim J, Ding L, Monteleone AJ, Owens GC, Phillips JJ, Everson RG, Nathanson D, Cloughesy TF, Li G, Liau LM, Hugo W, Kim W, Prins RM.
Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors.
J Clin Invest. 2023 Sep 1;133(17):e169314
. doi: 10.1172/JCI169314. PMID: 37655659. Laboratory investigation. ˍ




Yuan J, Liu J, Fan R, Liu Z.
Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients.
Radiat Res. 2023 Sep 1;200(3):289-295. doi: 10.1667/RADE-22-00198. PMID: 37797165∟. Observational study˰ ˍ



*

Corti C, Oldrati V, Papini M, Strazzer S, Poggi G, Romaniello R, Borgatti R, Urgesi C, Bardoni A.
Randomized clinical trial on the effects of a computerized cognitive training for pediatric patients with acquired brain injury or congenital malformation.
Sci Rep. 2023 Sep 4;13(1):14559
. doi: 10.1038/s41598-023-41810-1. PMID: 37666983. Interventional study. ˍ




Karschnia P, Dietrich J, Bruno F, Dono A, Juenger ST, Teske N, Young JS, Sciortino T, Häni L, van den Bent M, Weller M, Vogelbaum MA, Morshed RA, Haddad AF, Molinaro AM, Tandon N, Beck J, Schnell O, Bello L, Hervey-Jumper S, Thon N, Grau SJ, Esquenazi Y, Rudà R, Chang SM, Berger MS, Cahill DP, Tonn JC.
Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement ('low grade appearance') - a report of the RANO resect group.
Neuro Oncol. 2023 Sep 4:noad160
. doi: 10.1093/neuonc/noad160. PMID: 37665776. Observational study. ˍ



*

Roll W, Müther M, Böning G, Delker A, Warneke N, Gildehaus FJ, Schäfers M, Stummer W, Zeidler R, Reulen HJ, Stegger L.
First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study.
EJNMMI Res. 2023 Sep 4;13(1):78
. doi: 10.1186/s13550-023-01029-7. PMID: 37665396. Interventional study. ˍ




Sinha S, Avnon A, Perera A, Lavrador JP, Ashkan K.
Butterfly gliomas: a time for stratified management?
Neurosurg Rev. 2023 Sep 4;46(1):223
. doi: 10.1007/s10143-023-02126-w. PMID: 37665387. Observational study. ˍ




Chen W, Guo S, Wang Y, Shi Y, Guo X, Liu D, Li Y, Wang Y, Xing H, Xia Y, Li J, Wu J, Liang T, Wang H, Liu Q, Jin S, Qu T, Li H, Yang T, Zhang K, Wang Y, Ma W.
Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.
Cancer Med. 2023 Sep 5
. doi: 10.1002/cam4.6476. PMID: 37667984. Observational study. ˍ




Cifarelli CP, Vargo JA, Sener U, Cifarelli DT, Scoville D, Dabir A.
Intracranial intraoperative radiotherapy (IORT): evaluation of electrocorticography and peri-operative seizure risk.
J Neurooncol. 2023 Sep 5
. doi: 10.1007/s11060-023-04443-y. PMID: 37668944. Observational study˰ ˍ




Murtha AN, Zaki PG, Shepard MJ.
Letter to the editor: outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis.
J Neurooncol. 2023 Sep 5
. doi: 10.1007/s11060-023-04434-z. PMID: 37668942. Letter˰ ˍ




Wood MD, Beadling C, Neff T, Moore S, Harrington CA, Baird L, Corless C.
Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
Acta Neuropathol Commun. 2023 Sep 5;11(1):143
. doi: 10.1186/s40478-023-01644-4. PMID: 37670377. Laboratory investigation. ˍ




Wu YY, Chen KT, Chu YC, Yeh CC, Chen WC, Chen PY, Chang WH, Wei KC, Chen YC.
Neuropsychological impairment in primary malignant brain tumor patients with awake craniotomy: a hospital-based registration study.
J Neurooncol. 2023 Sep 5
. doi: 10.1007/s11060-023-04431-2. PMID: 37668943. Observational study˰ ˍ




Lohmeier J, Radbruch H, Brenner W, Hamm B, Hansen B, Tietze A, Makowski MR.
Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multimodal and integrative 18F-FET PET/fast-DKI approach.
Eur Radiol. 2023 Sep 6
. doi: 10.1007/s00330-023-10141-0. PMID: 37672058. Observational study. ˍ




He L, Zhang H, Li T, Yang J, Zhou Y, Wang J, Saidaer T, Liu X, Wang L, Wang Y.
Distinguishing Tumor Cell Infiltration and Vasogenic Edema in the Peritumoral Region of Glioblastoma at the Voxel Level via Conventional MRI Sequences.
Acad Radiol. 2023 Sep 7:S1076-6332(23)00407-5
. doi: 10.1016/j.acra.2023.08.008? PMID: 37689557. Observational study˰ ˍ



*

Ahluwalia MS, Rogers LR, Chaudhary R, Newton H, Ozair A, Khosla AA, Nixon AB, Adams BJ, Seon BK, Peereboom DM, Theuer CP.
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial.
Commun Med (Lond). 2023 Sep 8;3(1):120
. doi: 10.1038/s43856-023-00347-0. PMID: 37684373. Interventional study. ˍ



*

Nduom EK, Glod J, Brown DA, Fagan M, Dalmage M, Heiss J, Steinberg SM, Peer C, Figg WD, Jackson S.
Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis.
PLoS One. 2023 Sep 8;18(9):e0291068
. doi: 10.1371/journal.pone.0291068. PMID: 37682953. Interventional study protocol. ˍ




Cheng 程梦雨 M, Pang S, Wang Z, Zhao Y, Li W.
Clinical value of a nomogram model based on apparent diffusion coefficient values within 1 cm of the tumor cavity to predict postoperative progression of glioma.
World Neurosurg. 2023 Sep 9:S1878-8750(23)01266-4∟. doi: 10.1016/j.wneu.2023.09.015∟. PMID: 37696435∟. Observational study˰
ˍ




Rim MH, Barada F, Levitsky AM.
Recent and anticipated novel drug approvals for 2023 and 2024.
Am J Health Syst Pharm. 2023 Sep 9:zxad220
. doi: 10.1093/ajhp/zxad220. PMID: 37688502. Observational study˰ ˍ




Cui M, Liu Y, Zhou C, Chen H, Gao X, Liu J, Guo Q, Guan B, Ma X.
Resection of high-grade glioma involving language areas assisted by multimodal techniques under general anesthesia: a retrospective study.
Chin Neurosurg J. 2023 Sep 11;9(1):25
. doi: 10.1186/s41016-023-00340-5. PMID: 37691110. Observational study. ˍ




Seitzman BA, Anandarajah H, Dworetsky A, McMichael A, Coalson RS, Agamah AM, Jiang C, Gu H, Barbour DL, Schlaggar BL, Limbrick DD, Rubin JB, Shimony JS, Perkins SM.
Cognitive deficits and altered functional brain network organization in pediatric brain tumor patients.
Brain Imaging Behav. 2023 Sep 11
. doi: 10.1007/s11682-023-00798-y. PMID: 37695507. Observational study˰ ˍ




Aktekin EH, Kütük MÖ, Sangün Ö, Yazıcı N, Çaylaklı F, Erol İ, Sarıalioğlu F.
Late effects of medulloblastoma treatment: multidisciplinary approach of survivors.
Childs Nerv Syst. 2023 Sep 12
. doi: 10.1007/s00381-023-06146-1. PMID: 37698649. Observational study˰ ˍ




Dimov D, Brainman D, Berger B, Coras R, Grote A, Simon M.
The role of cytoreductive surgery in multifocal/multicentric glioblastomas.
J Neurooncol. 2023 Sep 12
. doi: 10.1007/s11060-023-04410-7. PMID: 37697210. Observational study. ˍ




Faye MD, Easaw J, De Robles P, Agnihotram R, Torres-Vasquez A, Lamonde F, Petrecca K, Owen S, Panet-Raymond V, Shenouda G, Souhami L, Azam M, Hossain B, Alkass J, Sabri S, Abdulkarim B.
Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma.
Neurooncol Adv. 2023 Sep 12;5(1):vdad106
. doi: 10.1093/noajnl/vdad106. PMID: 37771465. Interventional study. ˍ




Prins R, Everson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L.
Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients.
Res Sq [Preprint]. 2023 Sep 12:rs.3.rs-3287211. doi: 10.21203/rs.3.rs-3287211/v1. PMID: 37790490. Interventional study. ˍ




Sferruzza G, Finocchiaro G.
Glioblastoma immunotherapy: time for hope?
Neurol Sci. 2023 Sep 12
. doi: 10.1007/s10072-023-07066-3. PMID: 37700174. Letter˰ ˍ




Al Sharie S, Abu Laban D, Nazzal J, Iqneibi S, Ghnaimat S, Al-Ani A, Al-Hussaini M.
Midline Gliomas: A Retrospective Study from a Cancer Center in the Middle East.
Cancers (Basel). 2023 Sep 13;15(18):4545
. doi: 10.3390/cancers15184545. PMID: 37760513. Observational study. ˍ




Bruschi M, Midjek L, Ajlil Y, Vairy S, Lancien M, Ghermaoui S, Kergrohen T, Verreault M, Idbaih A, de Biagi CAO Jr, Liu I, Filbin MG, Beccaria K, Blauwblomme T, Puget S, Tauziede-Espariat A, Varlet P, Dangouloff-Ros V, Boddaert N, Le Teuff G, Grill J, Montagnac G, Elkhatib N, Debily MA, Castel D.
Diffuse Midline Glioma Invasion and Metastasis Rely on Cell-autonomous Signaling.
Neuro Oncol. 2023 Sep 13:noad161
. doi: 10.1093/neuonc/noad161. PMID: 37702430. Laboratory investigation. ˍ




Jabehdar Maralani P, Stewart J, Hiremath S, Lawrence L, Chan R, Lau A, Chen H, Chan A, Zeng LK, Tseng CL, Myrehaug S, Soliman H, Detsky J, Heyn C, Lim Fat M, Lipsman N, Sahgal A.
Relationship between apparent diffusion coefficient and survival as a function of distance from gross tumor volume on radiation planning MRI in newly diagnosed glioblastoma.
J Neurooncol. 2023 Sep 14
. doi: 10.1007/s11060-023-04440-1. PMID: 37707752. Observational study˰ ˍ




Hoogendijk R, van der Lugt J, Baugh J, Kline C, Kranendonk M, Hoving E, Kremer L, Wesseling P, Karim-Kos H, van Vuurden D.
Sex-related incidence and survival differences in pediatric high-grade glioma subtypes: A population-based cohort study.
iScience. 2023 Sep 15;26(10):107957. doi: 10.1016/j.isci.2023.107957. PMID: 37810231. Observational study.
ˍ